Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-04-09
1998-12-15
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142345, 544119, 544237, A01K 3150, C07D23730, C07D23734
Patent
active
058497412
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a novel fused pyridazine compound. In particular, the present invention relates to a novel fused pyridazine compound which is useful as drug.
DESCRIPTION OF RELATED BACKGROUND ART
Recently, studies on compounds exhibiting inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE") have proceeded and attempts have been made to apply such compounds to the prevention and treatment of circulatory failures such as hypertension, angina pectoris and myocardial infarct.
Known examples of the compound usable in the prevention and treatment of circulatory failures include quinazoline compounds disclosed in JP-A-29582/1975, 4H-3,1-benzoxazin-4-one compounds disclosed in WO JP-A-86894/1973, nitrogenous heterocyclic compounds disclosed in WO 93/07124 and 4-aminoquinazoline derivatives disclosed in EP 579496.
However, most of the compounds described above are not on the market and many of them have problems of solubility, in vivo dynamics and toxicity which must be solved prior to the use as drugs.
DISCLOSURE OF THE INVENTION
Under the above circumstances, the inventors of the present invention have started their studies for the purpose of finding a compound which exhibits an excellent cGMP-PDE inhibiting activity, has such a high water solubility as to be well absorbed into the living body, and is less toxic.
As a result of the studies, they have found that the above object can be attained by a fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. The present invention has been accomplished on the basis of this finding. ##STR2## {wherein ring C represents a five- or six-membered ring which may contain a heteroatom; group, optionally substituted lower alkoxy group, an optionally substituted cycloalkyl group, a nitro group, a cyano group, --NR.sup.2 R.sup.3 (wherein R.sup.2 and R.sup.3 represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R.sup.2 and R.sup.3 together with the nitrogen atom to which they are bonded may form a ring which may be substituted), --O--R.sup.9 (wherein R.sup.9 represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), --S--R.sup.10 (wherein R.sup.10 represents a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group), ##STR3## (wherein R.sup.11 represents a hydrogen atom, a lower alkyl group or an amino group; and m is an integer of 0 to 2), or an optionally protected carboxyl group, with the proviso that when n is 2 to 4, R.sup.1 's represent each independently a substituent selected from among those described above;
A represents a hydrogen atom, a halogen atom, --NR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group, or alternatively R.sup.4 and R5 together with the nitrogen atom to which they are bonded may form a ring which may be substituted), an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group;
X represents --NR.sup.6 -- (wherein R.sup.6 represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted arylalkyl group or an optionally substituted heteroarylalkyl group) or --N.dbd.; halogen atom, --NR.sup.7 R.sup.8 (wherein R7 and R.sup.8 represent each independently a hydrogen atom, an optionally substituted lower alkyl group, an acyl group, an optionally substituted arylalkyl group or an optio
REFERENCES:
patent: 3494921 (1970-02-01), Dorman
patent: 3971783 (1976-07-01), Barnish et al.
patent: 5089494 (1992-02-01), Iwase et al.
patent: 5324727 (1994-06-01), Iwase et al.
patent: 5462941 (1995-10-01), Iwase et al.
Kormendy et al., Acta Chimica Hungarica 112(4), 487-499 (1983).
Lee et al., Drugs Exptl. Clin. Res. XVII(7) 323-336 (1991).
Abstract for WO93/07124 (Apr. 1993).
Adachi Hideyuki
Ishibashi Keiji
Ishihara Hiroki
Kabasawa Yasuhiro
Kodama Kohtaro
Bernhardt Emily
Eisai Co. Ltd.
LandOfFree
Fused pyridazine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused pyridazine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused pyridazine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1458173